Tilray, Inc. was incorporated in 2018 in Canada and researches, cultivates, processes, and distributes medical cannabis. Tilray is a global company and sells its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa.
Tilray was the first Canadian-based marijuana stock to go public on a US exchange (Nasdaq), was one of the first medical cannabis companies in Canada to be issued a cultivation license and will be one of the main recipients to benefit when Canada open its recreational-marijuana market in October.
Tilray is expected to be one of the next cannabis companies to partner with a major alcoholic-beverage. Its been reported that Diageo is in discussions with several Canadian marijuana growers with Tilray being a top candidate. A partnership with a big beverage company could send this stock even higher.
Great news (at least in my opinion) was received last week. Tilray’ price went from $20 to $100 in a couple of months and had a market cap of $8.8 billion. The valuation was out of control, so Northland Capital Markets’ analyst Mike Grondahl downgraded Tilray from market perform from outperform. New Cannabis Ventures founding partner, Alan Brochstein, said, “there is a positive fundamental story going on, it’s just hard to tie the valuation into where we are right now.” Citron Research Executive Editor Andrew Left, the famous short seller said Tilray stock was overvalued and was more expensive than Canopy despite having no deal with a beverage maker.
Tilray will be a big player in the growing cannabis market and in the Canadian recreational market. A pullback might offer investors an opportunity to hope on board. The chart suggest to go long if price gets to the $60 level.
This post is my personal opinion. I’m not a financial advisor, this isn't financial advise. Do your own research before making investment decisions.